PHASE I TRIAL OF AUTOLOGOUS T CELLS ENGINEERED TO EXPRESS NY-ESO-1 TCR AND GENE EDITED TO ELIMINATE ENDOGENOUS TCR AND PD-1
Brief description of study
This is a Phase 1 first-in-human trial proposed to determine the safety profile and manufacturing feasibility of a single infusion of NYCE T cells on adult patients with myeloma, synovial sarcoma, and myxoid/round cell liposarcoma, and melanoma who have relapsed or refractory tumors expressing NY-ESO-1 antigen.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
myeloma
-
Age: Between 18 Years - 99 Years
-
Gender: All
Updated on
29 Jan 2020.
Study ID: 826672